Pink tomato gene

Some of these flavonoids also give the tomato cuticles a bright yellow cast -- the color component that is missing in the translucent pink skins of the mutants.

Using a lab system that's unique in Israel, and one of only a few in the world, Aharoni and his team are able to rapidly and efficiently identify hundreds of active plant substances called metabolites. A multidisciplinary approach developed over the past decade, known as metabolomics, enables them to create a comprehensive profile of all these substances in mutant plants and compare it with that of normal ones.

The research, carried out in Aharoni's lab by Dr. Avital Adato, Dr. Ilana Rogachev and research student Tali Mendel, showed that the differences between pink and red tomatoes go much deeper than skin color: The scientists identified about 400 genes whose activity levels are quite a bit higher or lower in the mutant tomatoes. The largest changes, appearing in both the plant cuticle and the fruit covering, were in the production of substances in the flavonoid family. The pink tomato also has less lycopene, a red pigment known to be a strong antioxidant that's been shown to be associated with reduced risk of cancer, heart disease and diabetes. In addition, alterations in the fatty composition of the pink tomato's outer layer caused its cuticle to be both thinner and less flexible that a regular tomato skin.

The researchers found that all of these changes can be traced to a mutation on a single gene known as SIMYB12. This gene acts as a 'master switch' that regulates the activities of a whole network of other genes, controlling the amounts of yellow pigments as well as a host of other substances in the tomato. Aharoni: 'Since identifying the gene, we found we could use it as a marker to predict the future color of the fruit in the very early stages of development, even before the plant has flowered. This ability could accelerate efforts to develop new, exotic tomato varieties, a process that can generally take over 10 years.'

Dr. Asaph Aharoni's research is supported by the De Benedetti Foundation-Cherasco 1547; and the Willner Family Foundation. Dr. Aharoni is the incumbent of the Adolpho and Evelyn Blum Career Development Chair of Cancer Research.